| 價(jià)格 | ¥397 | ¥666 | ¥1254 |
| 包裝 | 5mg | 10mg | 25mg |
| 最小起訂量 | 5mg |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-06-29 |
| 中文名稱(chēng):化合物 TB5 | 英文名稱(chēng):TB5 |
| CAS:948841-07-4 | 品牌: TargetMol |
| 產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 99.82% | 產(chǎn)品類(lèi)別: 抑制劑 |
| 貨號(hào): T001|T3596 |
| 名稱(chēng) | TB5 |
| 描述 | TB5 is a potent, selective and reversible inhibitor of hMAO-B. |
| 細(xì)胞實(shí)驗(yàn) | In vitro cytotoxicity of brominated thiophene chalcones and standard MAO inhibitors are tested in human HepG2 hepatic cancer cells at three different concentrations (1, 5 and 25 μM)[1]. |
| 激酶實(shí)驗(yàn) | Compounds are dissolved in DMSO (5 mg/mL) and diluted with PBS/EtOH (70:30).Kinetic analyses are carried out for TB5 and TB8. A set of Lineweaver–Burk plots are constructed in the absence and presence of various concentrations of compounds TB5 and TC8. The set consists of five graphs, each constructed by measuring MAO-B and MAO-A catalytic rates at different substrate concentrations (0.1-1 μM). The first Lineweaver–Burk plot is constructed in the absence of inhibitor, while the remaining four graphs are constructed in the presence of different concentrations of TB5 and TB8[1]. |
| 體外活性 | TB5 and TB8 interacts with the catalytic site of hMAO-B and hMAO-A with a competitive mode of inhibition. TB5 exhibits the best inhibitory activity and higher selectivity toward hMAO-B, with Ki and SI values of 0.11±0.01 μM and 13.18, respectively. hMAO-B inhibition by compound TB5 and hMAO-A inhibition by compound TB8 are completely reversed after 24 h of dialysis. Cytotoxicity studies show TB5 is nontoxic at 5 and 25 μM with cell viabilities of 95.75% and 84.59 %, respectively[1]. |
| 體內(nèi)活性 | Compounds are dissolved in DMSO (5 mg/mL) and diluted with PBS/EtOH (70:30). Kinetic analyses are carried out for TB5 and TB8 to understand the crucial interactions responsible for selectivity and potency. A set of Lineweaver–Burk plots are constructed in the absence and presence of various concentrations of compounds TB5 and TC8. The set consists of five graphs, each constructed by measuring MAO-B and MAO-A catalytic rates at different substrate concentrations (0.1-1 μM). The first Lineweaver–Burk plot is constructed in the absence of inhibitor, while the remaining four graphs are constructed in the presence of different concentrations of TB5 and TB8[1]. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 55 mg/mL (163.57 mM), Sonication is recommended. |
| 關(guān)鍵字 | TB-5 | TB5 | TB 5 | MonoamineOxidase | Monoamine Oxidase | MAO | Inhibitor | inhibit | hMAO-B |
| 相關(guān)產(chǎn)品 | Amitraz | β-Aminopropionitrile | Safinamide | 1,4-Naphthoquinone | Hydroxylamine hydrochloride | 4-Chlorochalcone | Methylene Blue trihydrate | Isatin | D-(-)-Quinic acid | Allylthiourea | Aminoacetone hydrochloride | Paeonol |
| 相關(guān)庫(kù) | 抑制劑庫(kù) | 線(xiàn)粒體膜蛋白靶向化合物庫(kù) | 抗帕金森病化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) | 線(xiàn)粒體靶向庫(kù) | 神經(jīng)信號(hào)分子庫(kù) | 抗衰老化合物庫(kù) | 抗抑郁癥化合物庫(kù) | 神經(jīng)退行性疾病化合物庫(kù) | 抗代謝疾病化合物庫(kù) | 細(xì)胞重編程化合物庫(kù) |
| 成立日期 | 2013-04-18 (14年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
| 員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
| 主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠(chǎng),試劑,定制,服務(wù) |
| 產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| 詢(xún)價(jià) |
河北冀肽生物科技有限公司
|
2026-07-22 | ||
| 詢(xún)價(jià) |
VIP1年
|
陜西締都醫(yī)藥有限責(zé)任公司
|
2026-04-22 | |
| 詢(xún)價(jià) |
VIP1年
|
海南瀚海致遠(yuǎn)生物科技有限公司
|
2026-06-10 | |
| ¥298.90 |
VIP3年
|
上海阿拉丁生化科技股份有限公司
|
2026-06-10 |